LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Atidarymo kaina

28.85 -0.21

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.83

Max

29.06

Pagrindiniai rodikliai
By Trading Economics
Pajamos	43M 13M
Pardavimai	29M 107M
Pelnas, tenkantis vienai akcijai	0.25
Pelno marža	12.139
Darbuotojai	524
EBITDA	16M 8.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+121.46% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	17M 1.5B
Ankstesnė atidarymo kaina	29.06
Ankstesnė uždarymo kaina	28.85

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-27 21:33; UTC

Uždarbis

Correction to Salesforce 1Q Sales, Profit Rise Article

2026-05-27 21:00; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare Agrees to Buy The College of Health Care Professions

2026-05-27 20:18; UTC

Uždarbis

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

2026-05-27 23:49; UTC

Rinkos pokalbiai

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

2026-05-27 23:39; UTC

Rinkos pokalbiai

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

2026-05-27 23:34; UTC

Rinkos pokalbiai

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

2026-05-27 23:34; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-27 23:08; UTC

Rinkos pokalbiai

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

2026-05-27 22:21; UTC

Rinkos pokalbiai

Salesforce Lays Out AI Monetization Strategy -- Market Talk

2026-05-27 21:29; UTC

Karštos akcijos

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

2026-05-27 21:08; UTC

Uždarbis

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

2026-05-27 21:02; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

2026-05-27 20:59; UTC

Įsigijimai, susijungimai, perėmimai

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

2026-05-27 20:55; UTC

Uždarbis

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

2026-05-27 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-27 20:48; UTC

Uždarbis

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

2026-05-27 20:45; UTC

Uždarbis

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

2026-05-27 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Webster Financial Stockholders Approve Sale to Banco Santander

2026-05-27 20:32; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026-05-27 20:32; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

2026-05-27 20:32; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

2026-05-27 20:30; UTC

Uždarbis

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

2026-05-27 20:30; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

2026-05-27 20:22; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026-05-27 20:16; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026-05-27 20:13; UTC

Uždarbis

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

2026-05-27 20:13; UTC

Uždarbis

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

2026-05-27 20:13; UTC

Uždarbis

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

2026-05-27 20:12; UTC

Uždarbis

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

2026-05-27 20:12; UTC

Uždarbis

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

121.46% į viršų

12 mėnesių prognozė

Vidutinis 65.13 USD 121.46%

Aukščiausias 100 USD

Žemiausias 33 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.